Using Latanoprost and Laser Treatment for Hair Loss
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment
PHASE1; PHASE2 · Egymedicalpedia · NCT06239324
This study is testing whether using Latanoprost with laser treatment can help people with Alopecia Areata grow back their hair.
Quick facts
| Phase | PHASE1; PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 30 Years to 35 Years |
| Sex | All |
| Sponsor | Egymedicalpedia (industry) |
| Locations | 1 site (Qinā) |
| Trial ID | NCT06239324 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Latanoprost, a medication known for its eyelash growth properties, combined with fractional Erbium-YAG laser treatment for patients suffering from Alopecia Areata, an autoimmune disorder that causes hair loss. The approach utilizes laser-assisted drug delivery to enhance the absorption of Latanoprost into the scalp, potentially leading to increased hair regrowth. The study aims to assess the safety and efficacy of this combined treatment in patients with localized stable Alopecia Areata. Participants will undergo a series of treatments while being monitored for hair regrowth and any side effects.
Who should consider this trial
Good fit: Ideal candidates are individuals of any sex with localized stable Alopecia Areata of at least 3 months duration.
Not a fit: Patients with scarring alopecia, alopecia totalis, alopecia universalis, or those with autoimmune dermatological diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with Alopecia Areata to regain hair growth.
How similar studies have performed: While the combination of Latanoprost and laser treatment is a novel approach, preliminary evidence suggests that transcutaneous drug delivery methods may enhance hair regrowth compared to topical therapies alone.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes with localized stable alopecia areata of the scalp of 3 months duration at least. Exclusion Criteria: 1. Acute or chronic infections. 2. Pregnant or lactating women. 3. Scarring alopecia. 4. Alopecia totalis , Alopecia universalis and ophiasis. 5. Autoimmune dermatological diseases.
Where this trial is running
Qinā
- Qena Hospital — Qinā, Egypt (RECRUITING)
Study contacts
- Principal investigator: Soheir AbdelHamid Ali, Assist. Prof. — Department of dermatology , Venerolgy and Andrology Faculty of Medicine Qena university
- Study coordinator: Maha Nabil Fahmy, Resident
- Email: mahanabilsoady@gmail.com
- Phone: 01012004848
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alopecia Areata